Review article

Trends in overall opportunistic illnesses, *Pneumocystis carinii* pneumonia, cerebral toxoplasmosis and *Mycobacterium avium* complex incidence rates over the 30 years of the HIV epidemic: a systematic review

Lara Coelho*, Valdiléa Gonçalves Veloso, Beatriz Grinsztejn, Paula Mendes Luz

Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

ARTICLE INFO

ABSTRACT

Background: The natural history of HIV infection has changed dramatically after the introduction of highly active antiretroviral therapy. Currently, opportunistic illnesses still represent a major cause of death and hospitalization in this population. In this study, we review the trends in opportunistic illnesses incidence rates and compare the results observed in high-income settings with that for low/middle-income settings, with special attention given to studies from Brazil.

Methods: We systematically searched Pubmed, Web of Science, Lilacs and Google scholar for publications on HIV associated opportunistic illness. Studies reporting rates based on person-time for all opportunistic illnesses and/or the three opportunistic infections of interest, namely, *Pneumocystis carinii* pneumonia, cerebral toxoplasmosis, and *Mycobacterium avium* complex were included.

Results: Significant reductions in the incidence rates were demonstrated for opportunistic illnesses overall and also for the specific opportunistic infections included in the present study, both in high and low/middle-income settings. Out of the 37 studies included in the present review, almost 70% were from high-income settings. All the studies conducted in low/middle-income settings were single center studies and four were from Brazil. We found no study from Brazil reporting annual incidence rates of opportunistic illnesses.

Conclusions: Opportunistic illnesses remain an important public health problem. To better guide health policies in low/middle-income settings, multicenter cohort studies should be encouraged. Studies from Brazil are urgently needed to assess the current burden of opportunistic illnesses in our population and to support the planning of HIV/AIDS health care services organization.

* *Corresponding author at*: Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, CEP 21045-900, Rio de Janeiro, Brazil.
E-mail addresses: lara.coelho@ipec.fiocruz.br, laraesteves@gmail.com (L. Coelho).

Introduction

The natural history of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) has changed dramatically since the onset of the epidemic in the 1980s. The landmark of this process was the introduction of highly active antiretroviral therapy (ART) in 1996. Despite the progress made in the treatment and control of HIV infection, HIV/AIDS persists as one of the main causes of death in the world, affecting individuals from both high-income and low-income settings.[1] In addition, although an increase in non-AIDS associated morbidity and mortality has been observed, opportunistic infections remain a major cause of hospitalization and death in people living with HIV/AIDS in high and low-income settings.[2–4]

Currently, in the post-ART period, opportunistic illnesses are mainly related with late diagnosis and/or presentation to care, non-adherence to ART and HIV resistance to antiretroviral drugs.[2,5] Late diagnosis and/or presentation to care is one of the most challenging aspects of the HIV epidemic. In Brazil, 34% of the patients still present with an opportunistic illness at the moment of ART initiation.[6] Furthermore, non-adherence to ART results in virologic failure and disease progression. Factors associated with non-adherence, such as low educational level, young age, unemployment, alcoholism and use of illicit drugs represent an important socioeconomic problem, in particular for low/middle-income settings.[7,8] Finally, multidrug resistance to antiretroviral drugs is a consequence of HIV exposure to ART, particularly in settings where non-adherence prevails.[9]

In this study, we review the trends in opportunistic illnesses incidence rates and compare the results observed in high-income settings (HIS) with that for low/middle-income settings (LMIS), with special attention given to studies from Brazil. We evaluate the impact ART has had in three specific opportunistic infections of particular importance to Brazil and contrast the patterns in the countries evaluated.

Search strategy and selection criteria

Publications related to AIDS-associated opportunistic illnesses incidence were identified by systematically searching in Pubmed, Web of Science, Lilacs and Google scholar. Publications were restricted to the following languages: English, Portuguese, and Spanish. The databases were searched for studies published until January 2013 using the following search terms and Boolean operators, for matches under any field: (incidence) AND (HIV OR human immunodeficiency virus) AND (AIDS-defining illness OR opportunistic infection OR opportunistic disease OR AIDS-related opportunistic infection OR AIDS-related opportunistic illness). For the Lilacs database, search terms were translated into Portuguese language and separate searches with each term were conducted. Titles and available abstracts were scanned for relevance identifying papers requiring further consideration. Bibliographies of relevant articles were also checked. Inclusion criteria consisted in (1) presence of a person-time denominator and (2) results for all opportunistic illnesses and/or the three oppor-

tunistic infections of interest, namely: *Pneumocystis carinii* pneumonia (PCP), cerebral toxoplasmosis (NTX) and *Mycobacterium avium* complex (MAC). Exclusion criteria included: (1) results given only for hospitalization and/or severe diseases, (2) results given relative terms only (that is, as incidence rate ratios, odds ratios or relative risks), (3) results given only for Immune Reconstitution Inflammatory Syndrome, and (4) results that aggregate death and opportunistic infections in one outcome. The results, inclusion and exclusion criteria are shown in Fig. 1.

Results

Thirty seven publications met the study's eligibility criteria, 25 from HIS and 12 studies from LMIS (Fig. 1).[2,10–45] Out of the 12 studies from LMIS, four were from Latin America, specifically from Brazil. Results from these studies are summarized in the next sections with incidence rates in 100 person-years (100 PY) format.

Opportunistic illnesses

Table 1 summarizes the findings for the incidence rate of opportunistic illnesses from 1984 to 2010 in HIS and LMIS. Depending on the study, incidence rates ranged from 2.3 to 12.3 times lower in the post-ART period compared to the pre-ART period.

In HIS, a multicenter study conducted in the United States using data from the HIV Outpatient Study (HOPS) cohort with no CD4+ cell count restriction of the study population reported that the incidence rate of opportunistic illnesses decreased from 9.24/100 PY in pre-ART period to 1.66/100 PY in post-ART period.[2] A more striking result was reported for the Eurosida cohort, an European multicenter cohort that included only patients with CD4+ cell counts less than 500 cells/mm^3 where the incidence rate of opportunistic illnesses decreased from 30.7/100 PY in the pre-ART period to 2.5/100 PY in the post-ART period.[10] Similarly, a study from Spain that included patients with CD4+ cell counts less than 500 cells/mm^3 reported significant decreases in the incidence rate of opportunistic illnesses, which went from 43.2/100 PY to 14.6/100 PY, in the pre and post-ART periods, respectively.[11] Other studies conducted in HIS can be found in Table 1, including results from England, Canada, Switzerland and Germany.

In LMIS, in a study from Thailand with no CD4+ cell count restriction of the study population, the incidence rate of opportunistic illnesses decreased from 19.1/100 PY in the absence of ART to 8.2/100 PY after ART use.[12] A study conducted in São Paulo in the period of 1986 through 1997, also with no CD4+ cell count restriction of the study population, reported an incidence rate of opportunistic illnesses of 12.24/100 PY in a supposedly pre-ART period.[13] Another study conducted with the same population during the period from 1987 to 2002 estimated a lower incidence rate of opportunistic illnesses of 4.6/100 PY.[14] A study from Rio de Janeiro, that included only patients with CD4+ counts less than 100 cells/mm^3 in the period of 1997 to 1999, found an incidence rate of opportunistic illnesses of 29/100 PY a supposedly post-ART period.[15] Other

Table 1 – Incidence rates for opportunistic illnesses among HIV-infected individuals from high and low/middle-income settings.

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
High-income settings				
Cain, 2009, American Journal of Epidemiology	Baltimore, Pittsburgh, Chicago and Los Angeles, US, MACS cohort	1984[a] to April 2007	Entire period: 5.23/100 PY; Before 1996: 7.53/100 PY; After1996: 2.19/100 PY	Patient inclusion criteria: no CD4 criteria, MSM only; Disease definition: CDC 1993, considers only the first ADI after cohort enrollment
Mocroft, 1999, Journal of Acquired Immune Deficiency Syndromes	London, UK, Royal Free Center for HIV Medicine	1987[a] to 1998[a]	Before 1992: 27.4/100 PY; 1992–1993: 16.8/100 PY; 1994: 17.9/100 PY; 1995: 19.3/100 PY; 1996: 16.7/100 PY; 1997: 6.9/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: CDC 1993, considers only the first ADI after cohort enrollment
San-Andres, 2003, Clinical Infectious Diseases	Madrid, Spain, University Hospital	January 1989–1997[a]	1989–1991: 36.4/100 PY; 1992: 43.2/100 PY; 1993: 39.0/100 PY; 1994: 32.4/100 PY; 1995: 32.0/100 PY; 1996: 30.9/100 PY; 1997: 14.6/100 PY	Patient inclusion criteria: CD4 less than 500 cells/mm^3 or previous AIDS diagnosis; Disease definition: not clearly stated, likely considers all ADI[b] episodes after cohort enrollment
Charurat, 2004, Journal of Women's Health	4 states in US and Puerto Rico, WITS Cohort	December 1989 to June 2002	Before Feb/1994: 4.52/100 PY; Mar/1994 to Jul/1996: 5.09/100 PY; After Aug/1996: 1.22/100 PY	Patient inclusion criteria: no CD4 criteria, only women without previous diagnosis of AIDS; Disease definition: CDC 1993; considers only the first ADI after cohort enrollment
Kaplan, 2000, Clinical Infectious Diseases	10 US cities, Adults/Adolescents Spectrum of HIV Disease (ASD) Study	1992[a] to September 1999	1996–1998: 16/100 PY[c]	Patient inclusion criteria: no CD4 criteria; Disease definition: not clearly stated, likely considers all ADI[d] episodes after cohort enrollment
Forrest, 1998, Clinical Infectious Diseases	British Columbia, Canada, British Columbia Center for Excellence in HIV/AIDS	January 1994 to December 1996	1994: 8/100 PY; 1996: 2.2/100 PY	Patient inclusion criteria: no CD4 criteria, included only patients in use of antiretroviral drugs; Disease definition: CDC 1993; considers only the first ADI after cohort enrollment
Mocroft, 2000, Lancet	51 centers in Europe, Eurosida cohort	May 1994 to spring 1999[a]	1994: 30.7/100 PY; 1998: 2.5/100 PY[c]	Patient inclusion criteria: CD4 < 500 cells/mm^3; Disease definition: CDC 1993, considers the first ADI after cohort enrollment
Buchacz, 2010, AIDS	12 centers in US, HOPS cohort	January 1994 to December 2007	1994–1997: 9.24/100 PY; 1998–2002: 2.96/100 PY; 2003–2007: 1.66/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: CDC 1993[e]; considers only the first ADI after cohort enrollment

Table 1 (*Continued*)				
First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
Ledergerber, 1999, Journal of the American Medical Association	7 centers in Switzerland, Swiss HIV Cohort Study	September 1995 to March 1999	Before to ART use: 15.1/100 PY; after ART use: 3.57/100 PY	Patient inclusion criteria: no CD4 criteria, included patients who started ART between September 1995 and December 1997. Disease definition: CDC 1993, considers only the first ADI after cohort enrollment
Wohl, 2003, Aids Patient Care and STDs	10 US cities, ASD cohort	1996[a] to 2000[a]	US born: 21.0/100 PY; Mexican born: 16.6/100 PY; Central American born: 13.9/100 PY	Patient inclusion criteria: no CD4 criteria; included US born Latinos, Mexican born Latinos and Central American Latinos. Disease definition: not clear stated, apparently included all ADI presented in the study period.
Plettenberg, 2011, Infection	Germany, KompNet cohort	1996[a] to 2010[f]	Group 1: 1.38/100 PY; Group 2: 0.78/100 PY	Patient inclusion criteria: patients who started antiretroviral treatment.[g] Disease definition: included the first episode of an ADI after antiretroviral therapy.
Low/middle-income settings				
Fonseca, 1999, International Journal of Epidemiology	São Paulo, Brazil, University of São Paulo	1986[a] to June 1997	12.24/100 PY (converted from 10.2/1000 PM)	Patient inclusion criteria: asymptomatic patients; Disease definition: CDC 1987, modified to include pulmonary tuberculosis as an AIDS defining-condition, considers only the first ADI after cohort enrollment
Casseb, 2003, AIDS Patient care and STDs	São Paulo, Brazil, University of São Paulo	October 1987 to February 2002	4.6/100 PY (converted from 3.84/1000PM)	Patient inclusion criteria: asymptomatic patients; Disease definition: CDC 1987, considers only the first ADI after cohort enrollment
Badri, 2005, The Southern African Journal of HIV Medicine	Cape Town, South Africa, Cape Town AIDS Cohort (CTAC)	1992[a] to December 2000	21.34/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: WHO 1990, considers all ADI episodes after cohort enrollment
Losina, 2007, Antiviral Therapy	Abidjan, Ivory Coast, Cotrimo CI ANRS 059 and Cotrame ANRS1203	1996[a] to July 2003	Cotrimoxazole alone: CD4 less than 50 cells/mm³: 20.17/100 PY; CD4 above 200 cells/mm³: 3.54/100 PY; Cotrimoxazole plus ART (0–6 months): CD4 less 50 cells/mm³: 20.22/100 PY, CD4 > 200 cells/mm³: 2.79/100 PY; Cotrimoxazole plus ART (>6 months): CD4 < 50 cells/mm³: 6.84/100 PY, CD4 > 200 cells/mm³: 1.68/100 PY	Patient inclusion: Patients participating in Cotrimo ANRS and Cotrame ANRS studies. Disease definition: considers only the first ADI[h] presented in each period[i] of study. Results were stratified by use of cotrimoxazole prophylaxis, ART and CD4 counts.

Table 1 (Continued)

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
Gadelha, 2002, Rev Inst Med Trop Sao Paulo	Rio de Janeiro, Brazil, IPEC cohort	September 1997 to December 1999	29/100 PY[j]	Patient inclusion criteria: at least one CD4 < 100 cells/mm^3, included patients who started ART between September 1995 and December 1997. Disease definition: CDC 1993, considers the first ADI after cohort enrollment
De Beaudrap, 2010, BMC Infectious Diseases	Senegal, Initative Sénégalaise d'Acèss aux médicaments Antiretroviraux[k]	August 1998 to April 2008	First year after ART initiation: 20.5/100 PY. Over the fourth year after ART initiation: 4.3/100 PY	Patient inclusion criteria: no CD4 criteria. Disease definition: CDC 1993, considered the first episode of each ADI presented after ART initiation. Results were stratified by timing of ART use
Podlasin, 2006, Infection	10 centers in Poland	2000[a] to 2002[a]	Total: 2.4/100 PY; 2000: 6.8/100 PY; 2001: 6.5/100 PY; 2002: 4.8/100 PY	Patient inclusion criteria: none; Disease definition: CDC 1993, not clearly stated, likely considers all ADI after cohort enrollment
Rojanawiwat, 2011, International Health	Lampang, Thailand, Governmental Referral Hospital[l]	July 2000 to October 2004	Prior to ART: 19.1/100 PY; After ART use: 8.2/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: included the first episode of all ADI[m] presented by the patient

ADI: AIDS defining illness; CDC: Centers for Disease Control; CMV: cytomegalovirus; MAC: *Mycobacterium avium* complex; MSM: men who have sex with men; PCP: *Pneumocystis carinii* pneumonia.

[a] Month not specified.

[b] Does not specify the criteria used for ADI, the results include: Esophageal candidiasis, PCP, tuberculosis, wasting syndrome, cerebral toxoplasmosis, Kaposi's sarcoma, AIDS dementia complex, progressive multifocal leukoencephalopathy, primary brain lymphoma, CMV disease, MAC, non-Hodgkin lymphoma, cryptosporidiosis, recurrent pneumonia, cryptococcosis, chronic herpes simplex, invasive cervical cancer.

[c] Results for other years shown in figure format only, thus not reported here.

[d] Diseases included: PCP, disseminated MAC, cerebral toxoplasmosis, Kaposi's sarcoma, CMV retinitis, esophageal candidiasis, cryptococcosis.

[e] Excluded diseases: recurrent pneumonia, *Salmonella* septicemia and wasting syndrome.

[f] Time inferred from information contained in the text.

[g] Patients were separated into two groups: Group 1: patients who started ART with CD4 between 250 and 349 cells/mm^3; Group 2: patients who started ART with CD4 between 350 and 450 cells/mm^3.

[h] Diseases included: severe bacterial infections (pneumonia, enteritis, bacteremia, invasive urogenital infection), malaria, cerebral toxoplasmosis, isosporosis, PCP, extrapulmonar cryptococosis, esophageal candidiasis, tuberculosis, MAC, other WHO clinical stage 3 and 4.

[i] In the first period (until December 1998), patients received cotrimoxazole prophylaxis. In the second period (after December 1998) patients received ART plus cotrimoxazole prophylaxis (the later period was separated in the first 6 months after ART initiation and after 6 months of ART initiation).

[j] Data from de prospective period.

[k] Antiretroviral drugs available for free since December 2003.

[l] In 2002 the government introduced the co-formulation stavudine, lamivudine and nevirapine (on a pilot basis). The use of this medication gradually increased especially after 2004.

[m] Does not specify the criteria used for ADI, the results include: tuberculosis, PCP, cryptococcal meningitis, penicilliosis, esophageal candidiasis, herpes zoster, cerebral toxoplasmosis, CMV retinitis.

Fig. 1 – Search strategy and papers selection flowchart.

studies conducted in LMIS can be found in Table 1 and include results from South Africa, Ivory Coast, Senegal and Poland.

Pneumocystis carinii pneumonia

Table 2 summarizes the findings for PCP incidence rates from 1982 to 2008 in HIS and LMIS. Depending on the study, incidence rates ranged from 2.0 to 15.6 times lower in the post-ART period compared to the pre-ART period.

In HIS, a study conducted in one center in England including all HIV-infected individuals showed that the incidence rate of PCP decreased from 9.1/100 PY in the pre-ART period (before 1992) to 1.9/100 PY in the post-ART period (in 1997).[16] An even more dramatic result was reported in a study from San Francisco, United States, that used local surveillance data of the HIV-infected population and showed that the incidence rate of PCP dropped from 9.5/100 PY in pre-ART period (1993–1995) to 0.85/100 PY in post-ART period (2001–2008).[17] Other studies conducted in HIS can be found in Table 2, including results from France, Spain, Switzerland and Germany.

In LMIS, a study from Taiwan that included all HIV-infected individuals estimated that the incidence rate of PCP decreased from 70.5/100 PY in the pre-ART period (1995) to 9.2/100 PY in the post-ART period (1999).[18] In addition, a study from Thailand that, again, included all HIV-infected patients reported an incidence rate of PCP decreasing from 4.7/100 PY in the absence of ART to 0.3/100 PY after ART use.[12] Other studies conducted in LMIS can be found in Table 2 and include results from South Africa and Poland. Unfortunately, we found no study from Brazil.

Cerebral toxoplasmosis

Table 3 summarizes the findings for NXT incidence rate from 1985 to 2010 in HIS and LMIS. Depending on the study, incidence rates varied from 1.2 to 8.0 times lower in the post-ART period compared to the pre-ART period.

In HIS, a multicenter cohort (Multicenter AIDS Cohort Study – MACS) of HIV-infected men who have sex with men from the United States reported that the incidence rate of NTX decreased from 0.54/100 PY in pre-ART period (1990–1992) to 0.22/100 PY in post-ART period (1996–1998).[19] Data of the Swiss cohort (multicenter cohort) confirmed this trend showing that the incidence rate of NTX among HIV-infected individuals who started antiretroviral therapy between 1995 and 1997 decreased from 1.45/100 PY before ART use to 0.18/100 PY after ART use.[20] Also in HIS, in a multicenter study from United Kingdom conducted among HIV-infected individuals reported that the incidence rate of NTX decreased from 0.32/100 PY in the pre-ART period (1996–1997) to 0.04/100 PY in the post-ART period (1996–2007).[21] Other studies conducted in HIS can be found in Table 3, including results from England, France, Spain, Switzerland and Germany.

In LMIS, a study from Thailand that included all HIV-infected patients estimated a reduction in the incidence rate of NTX from 1.2/100 PY in the absence of ART to 1.0/100 PY after ART use.[12] Data from LMIS also include a study from South Africa, with no CD4$^+$ cell count restriction of the study population, with an incidence rate of NTX of 0.15/100 PY in the period of 1992–2000.[22] Again, we unfortunately did not find any study from Brazil.

Mycobacterium avium complex disease

Table 4 summarizes the findings for MAC incidence rate from 1985 to 2008 in HIS and LMIS. Depending on the study, incidence rates ranged from 2.4 to 25.8 times lower in the post-ART period compared to the pre-ART period.

In HIS, a surveillance study from San Francisco (United States), with no CD4$^+$ cell count restriction of the study population, reported an incidence rate of MAC decreasing from 8.52/100 PY in pre-ART period (1993–1995) to 0.32/100 PY in post-ART period (2001–2008).[17] One study from Spain, that included only patients with CD4$^+$ counts less than 500 cells/mm^3, reported that the incidence rate of MAC decreased from 2.9/100 PY in pre-ART period (1992) to 0.6/100 PY in post-ART period (1997).[11] In addition, data from the Swiss Cohort for patients with CD4$^+$ counts less than 50 cells/mm^3, showed an incidence rate of MAC decreasing from 8.8/100 PY in pre-ART period (1990–1996) to 1.4/100 PY in post-ART period (1997–1999).[23] Other studies conducted in HIS can be found in

Table 2 – Incidence rate for *Pneumocystis carinii* pneumonia among HIV-infected individuals from high and low/middle-income settings.

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
High-income settings				
Mocroft, 1998, Archives of Internal Medicine	London, England, Chelsea and Westminster Hospital and The Royal Free Hospital	1982[a] to July 1995	6.22/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only first episode after cohort enrollment
Bacellar, 1994, Journal of Infectious Diseases	Baltimore, Pittsburgh, Chicago and Los Angeles, US, MACS cohort	1985[a] to 1993[a]	No antiretroviral nor PCP prophylaxis: 3.1/100 PY; Only antiretroviral: 1.8/100 PY; Antiretroviral and PCP prophylaxis: 2.4/100 PY	Patient inclusion criteria: CD4 < 100 cells/mm^3, MSM only; Disease definition: considers only the first episode after cohort enrollment. Results stratified by use of antiretroviral[b] and/or PCP prophylaxis
Yazdanpanah, 2001, International Journal of Epidemiology	France, Tourcoing and Aquitaine cohorts	January 1987 to December 1995	>500 cells/mm^3: 0.4/100 PY; 301–500 cells/mm^3: 0.5/100 PY; 201–300 cells/mm^3: 1.6/100 PY; 101–200 cells/mm^3: 3.1/100 PY; 51–100 cells/mm^3: 6.7/100 PY; >50 cells/mm^3: 11.4/100 PY;	Patient exclusion criteria: patients in use of antiretroviral therapy other than zidovudine monotheray and prophylaxis; patients with less than 3 CD4 counts; patients with prior PCP diagnosis or PCP diagnosis in the first cohort visit and those in use of PCP prophylaxis. Disease definition: only the first case after cohort enrollment. Results stratified by CD4 counts
Mocroft, 1999, Journal of Acquired Immune Deficiency Syndromes	London, England, Royal Free Center for HIV Medicine	1987[a] to 1998[a]	Before 1992: 9.1/100 PY; 1992–1993: 5.3/100 PY; 1994: 3.5/100 PY; 1995: 6.4/100 PY; 1996: 4.0/100 PY; 1997: 1.9/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: only first ADI was considered after cohort enrollment
Moore, 1996, Annals of Internal Medicine	Baltimore, US, Johns Hopkins Clinical Cohort	July 1989 to April 1995	8.9/100 PY	Patient inclusion criteria: CD4 < 300 cells/mm^3; Disease definition: only first episode considered after cohort enrollment
San-Andres, 2003, Clinical Infectious Diseases	Madrid, Spain, University Hospital	January 1989 to 1997[a]	1989–1991: 5.5/100 PY; 1992: 5.4/100 PY; 1993: 3.5/100 PY; 1994: 3.4/100 PY; 1995: 3.0/100 PY; 1996: 3.3/100 PY; 1997: 0.6/100 PY	Patient inclusion criteria: CD4 < 500 cells/mm^3 or previous diagnosis of an ADI; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Charurat, 2004, Journal of Women's Health	4 states in US and Puerto Rico, WITS Cohort	December 1989 to June 2002	Before February 1994: 0.44/100 PY March 1994 to July 1996: 0.86/100 PY After August 1996: 0.42/100 PY	Patient inclusion criteria: no CD4 criteria, women only, without previous diagnosis of AIDS; Disease definition: only first episode considered after cohort enrollment
Moorman, 1998, Journal of Acquired Immune Deficiency Syndromes	8 US cities, HOPS cohort	January 1992 to June 1996	4.6/100 PY	Patient inclusion criteria: patients in use of PCP prophylaxis for at least 3 months[c]; Disease definition: all episodes considered after cohort enrollment
Brodt, 1997, AIDS	Frankfurt, Germany, Frankfurt AIDS Cohort	January 1992 to March 1997	1992: 17.8/100 PY; 1993: 18.2/100 PY; 1994: 16.3/100 PY; 1995: 9.9/100 PY; 1996: 6.4/100 PY	Patient inclusion criteria: CD4 < 200 cells/mm^3, MSM only; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment

Table 2 (Continued)

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
Kaplan, 2000, Clinical Infectious Diseases	10 US cities, Adults/Adolescents Spectrum of HIV Disease (ASD) Study	1992[a] to September 1999	1996–1998: 4.7/100 PY[d]	Patient inclusion criteria: no CD4 criteria; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Schwarcz, 2013, AIDS	San Francisco, US, SFDHP	January 1993 to December 2008	1993–1995: 9.5/100 PY; 1996–2000: 2.15/100 PY; 2001–2008: 0.84/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only the first episode after cohort enrollment
Ledergerber, 1999, Journal of the American Medical Association	7 centers in Switzerland, Swiss HIV Cohort Study	September 1995 to March 1999	Before ART use: 2.35/100 PY, after ART use: 0.22/100 PY	Patient inclusion criteria: no CD4 criteria, patients who started ART between September 1995 and December 1997. Disease definition: only first episode considered after cohort enrollment
Mocroft, 2000, Lancet	51 centers in Europe, Eurosida cohort	December 1995 to spring 1999[a]	Non-ART regimens: 2.3/100 PY; ART regimens: 0.5/100 PY	Patient inclusion criteria: CD4 < 500 cells/mm^3; Disease definition: considers the first episode after cohort enrollment
Wohl, 2003, Aids Patient Care and STDs	10 US cities, ASD cohort	1996[a] to 2000[a]	US born: 3.6/100 PY; Mexican born: 2.7/100 PY; Central American born: 1.3/100 PY	Patient inclusion criteria: no CD4 criteria; included US born Latinos, Mexican born Latinos and Central American Latinos. Disease definition: not clear stated, apparently included all episodes presented in the study period
Low/middle-income settings				
Badri, 2005, The Southern African Journal of HIV Medicine	Cape Town, South Africa, Cape Town AIDS Cohort (CTAC)	1992[a] to December 2000	1.19/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Hung, 2000, Journal of Acquired Immune Deficiency Syndromes	Taiwan, National Taiwan University Hospital	June 1994 to June 1999	1995: 70.5/100 PY; 1999: 9.2/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only the first episode after cohort enrollment
Holmes, 2006, Journal of Acquired Immune Deficiency Syndromes	Cape Town, South Africa, University of Cape Town cohort	1994[a] to 2000[a]	CD4 < 50: 8.1/100 PY; CD4 51–200: 0.6/100 PY; CD4 201–350: 0.3/100 PY; CD4 > 350: 0	Patient inclusion criteria: patients with at least two CD4 cell counts; Disease definition: WHO stage III and IV, considers only first episode considered after cohort enrollment. Results were stratified by CD4
Podlasin, 2006, Infection	10 centers in Poland	2000[a] to 2002[a]	2000: 0.89/100 PY; 2001: 0.82/100 PY; 2002: 0.5/100 PY	Patient inclusion criteria: none; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Rojanawiwat, 2011, International Health	Lampang, Thailand, Governmental Referral Hospital[e]	July 2000 to October 2004	Prior to ART: 4.7/100 PY; After ART use: 0.3/100 PY	Patient inclusion criteria: none; Disease definition: not clearly stated, likely considers the first episode after cohort enrollment

ADI: AIDS defining illness; ART: highly active antiretroviral therapy; MSM: men who have sex with men; PCP: *Pneumocytis carinii* pneumonia.

[a] Month not specified.

[b] Zidovudine, didanosine or both.

[c] PCP prophylaxis was prescribed for patients with CD4 count less than 200 cells/mm^3 or considered at risk by their clinicians (even if CD4 > 200 cells/mm^3).

[d] Results for other years shown in figure format only, thus not reported here.

[e] In 2002 the government introduced the co-formulation stavudine, lamivudine and nevirapine (on a pilot basis). The use of this medication gradually increased especially after 2004.

Table 3 – Incidence rates for cerebral toxoplasmosis among HIV-infected individuals from high and low/middle-income settings.

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
High-income settings				
Bacellar, 1994, Journal of Infectious Diseases	Baltimore, Pittsburgh, Chicago and Los Angeles, US, MACS cohort	1985[a] to 1993[a]	No antiretroviral nor PCP prophylaxis: 6.9/100 PY; Only antiretroviral: 6.0/100 PY; Antiretroviral and PCP prophylaxis: 14.8/100 PY	Patient inclusion criteria: CD4 < 100 cells/mm^3, MSM only; Disease definition: considers only the first episode after cohort enrollment. Results stratified by use of antiretroviral[b] and/or PCP prophylaxis
Yazdanpanah, 2001, International Journal of Epidemiology	France, Tourcoing and Aquitaine cohorts	January 1987 to December 1995	>500 cells/mm^3: 0.1/100 PY; 301–500 cells/mm^3: 0.6/100 PY; 201–300 cells/mm^3: 1.1/100 PY; 101–200 cells/mm^3: 2.0/100 PY; 51–100 cells/mm^3: 3.9/100 PY; >50 cells/mm^3: 12.6/100 PY	Patient exclusion criteria:patients in use of antiretroviral therapy other than zidovudine monotheray and prophylaxis; patients with less than 3 CD4 counts; patients with prior NTX diagnosis or with NTX diagnosis in the first cohort visit and those in use of NTX prophylaxis. Disease definition: only the first case after cohort enrollment. Results stratified by CD4 counts
Moore, 1996, Annals of Internal Medicine	Baltimore, US, Johns Hopkins Clinical Cohort	July 1989 to April 1995	2.3/100 PY	Patient inclusion criteria: CD4 < 300 cells/mm^3; Disease definition: considers only the first episode after cohort enrollment
San-Andres, 2003, Clinical Infectious Diseases	Madrid, Spain, University Hospital	January 1989 to 1997[a]	1989–1991: 2.1/100 PY, 1992: 2.9/100 PY, 1993: 2.4/100 PY, 1994: 0.8/100 PY, 1995: 1.1/100 PY, 1996: 1.0/100 PY, 1997: 1.8/100 PY	Patient inclusion criteria: CD4 < 500 cells/mm^3 or previous diagnosis of AIDS; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Sacktor, 2001, Neurology	Baltimore, Pittsburgh, Chicago and Los Angeles, US, MACS cohort	January 1990 to December 1998	1990–1992: 0.54/100 PY, 1993–1995: 0.38/100 PY, 1996–1998: 0.22/100 PY	Patient inclusion criteria: no CD4 criteria, MSM only; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Brodt, 1997, AIDS	Frankfurt, Germany, Frankfurt AIDS Cohort	January 1992 to March 1997	1992: 10.6/100 PY, 1993: 6.1/100 PY, 1994: 3.9/100 PY, 1995: 4.0/100 PY, 1996: 2.6/100 PY	Patient inclusion criteria: CD4 < 200 cells/mm^3, MSM only; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Ledergerber, 1999, Journal of the American Medical Association	7 centers in Switzerland, Swiss HIV Cohort Study	September 1995 to March 1999	Before ART use: 1.45/100 PY, after ART use: 0.18/100 PY	Patient inclusion criteria: no CD4 criteria, patients who started ART between September 1995 and December 1997. Disease definition: considers only the first episode after cohort enrollment

Table 3 (*Continued*)

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
Wohl, 2003, Aids Patient Care and STDs	10 US cities, ASD cohort	1996[a] to 2000[a]	US born: 0; Mexican born: 0.5/100 PY; Central American born: 0.7/100 PY	Patient inclusion criteria: no CD4 criteria; included US born Latinos, Mexican born Latinos and Central American Latinos. Disease definition: not clear stated, likely considers all episodes presented in the study period
Garvey, 2011, European Journal of Neurology	10 UK HIV centers, CHIC (UK Collaborative HIV Cohort)	January 1996 to December 2007	Total: 0.12/100 PY; 1996–1997: 0.32/100 PY, 1998–1999: 0.11/100 PY, 2000–2001: 0.15/100 PY, 2002–2003: 0.11/100 PY, 2004–2005: 0.09/100 PY, 2006–2007: 0.04/100 PY	Patient inclusion criteria: none; Disease definition: considers only the first episode after cohort enrollment
Riveiro-Barciela, 2013, HIV medicine	Barcelona, Spain	January 2000 to December 2010	2000 to June 2005: 0.32/100 PY; July 2005–2010: 0.11/100 PY	Patient inclusion criteria: none; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Low/middle-income settings				
Badri, 2005, The Southern African Journal of HIV Medicine	Cape Town, South Africa, Cape Town AIDS Cohort (CTAC)	1992[a] to December 2000	0.15/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Holmes, 2006, Journal of Acquired Immune Deficiency Syndromes	Cape Town, South Africa, University of Cape Town cohort	1994[a] to 2000[a]	CD4 < 50: 1.2/100 PY; CD4 51–200: 0; CD4 201–350: 0; CD4 > 350: 0	Patient inclusion criteria: patients with at least two CD4 cell counts; Disease definition: WHO stage III and IV; considers only first episode after cohort enrollment. Results were stratified by CD4
Rojanawiwat, 2011, International Health	Lampang, Thailand, Governmental Referral Hospital[c]	July 2000 to October 2004	Before ART use: 1.2/100 PY, After ART use: 1.0/100 PY	Patient inclusion criteria: none; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment

ART: highly active antiretroviral therapy; MSM: men who have sex with men; NTX: Cerebral toxoplasmosis; PCP: *Pneumocytis carinii* pneumonia.

[a] Month not specified.

[b] Zidovudine, didanosine or both.

[c] In 2002 the government introduced the co-formulation stavudine, lamivudine and nevirapine (on a pilot basis). The use of this medication gradually increased especially after 2004.

Table 4 – Incidence rate of *Mycobacterium avium* complex among HIV-infected individuals from high and low/middle-income settings.

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
High-income settings				
Bacellar, 1994, Journal of Infectious Diseases	Baltimore, Pittsburgh, Chicago and Los Angeles, US, MACS cohort	1985[a] to 1993[a]	No antiretroviral nor PCP prophylaxis: 6.9/100 PY; Only antiretroviral: 6.0/100 PY; Antiretroviral and PCP prophylaxis: 14.8/100 PY	Patient inclusion criteria: CD4 < 100 cells/mm^3, MSM only; Disease definition: CDC 1993; considers only the first episode of each ADI after cohort enrollment. Results stratified by use of antiretroviral[b] and/or PCP prophylaxis
Chaisson, 1992, American review of respiratory disease	Multicenter observational cohort in US	April 1987 to 1990[c]	8.6/100 PY	Patient inclusion criteria: patients with AIDS diagnoses defined by PCP, an opportunistic disease other than PCP and CD4 < 250 cells/mm^3, or AIDS related complex and CD4 < 250 cells/mm^3; Disease definition: not clearly stated, likely considers only the first episodes after cohort enrollment
Yazdanpanah, 2001, International Journal of Epidemiology	France, Tourcoing and Aquitaine cohorts	January 1987 to December 1995	>500 cells/mm^3: 0.0/100 PY; 301–500 cells/mm^3: 0.2/100 PY; 201–300 cells/mm^3: 0.3/100 PY; 101–200 cells/mm^3: 1.0/100 PY; 51–100 cells/mm^3: 1.9/100 PY; >50 cells/mm^3: 9.5/100 PY	Patient exclusion criteria: patients in use of antiretroviral therapy other than zidovudine monotheray and prophylaxis; patients with less than 3 CD4 counts; excluded patients with prior MAC diagnosis or with MAC diagnosis in the first cohort visit and those in use of MAC prophylaxis. Disease definition: considers only the first case after cohort enrollment. Results stratified by CD4 counts
Mocroft, 1999, Journal of Acquired Immune Deficiency Syndromes	London, England, Royal Free Center for HIV Medicine	1987[c] to 1998[c]	Before 1992: 1.1/100 PY, 1992–1993: 3.8/100 PY, 1994: 4.1/100 PY, 1995: 4.1/100 PY, 1996: 2.7/100 PY, 1997: 1.0/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only the first episode after cohort enrollment
Moore, 1996, Annals of Internal Medicine	Baltimore, US, Johns Hopkins Clinical Cohort	July 1989 to April 1995	7.4/100 PY	Patient inclusion criteria: CD4 < 300 cells/mm^3; Disease definition: considers only the first episode after cohort enrollment
San-Andres, 2003, Clinical Infectious Diseases	Madrid, Spain, University Hospital	January 1989 to 1997[c]	1989–1991: 1.5/100 PY, 1992: 2.9/100 PY, 1993: 1.5/100 PY, 1994: 1.1/100 PY, 1995: 1.9/100 PY, 1996: 2.5/100 PY, 1997: 0.6/100 PY	Patient inclusion criteria: CD4 < 500 cells/mm^3 or previous diagnosis AIDS; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Charurat, 2004, Journal of Women's Health	4 states in US and Puerto Rico, WITS Cohort	December 1989 to June 2002	Before February 1994: 0.32/100 PY; March 1994 to July 1996: 0.23/100 PY; After August 1996: 0.12/100 PY	Patient inclusion criteria: no CD4 criteria, women only, without previous diagnosis of AIDS; Disease definition: considers only the first episode after cohort enrollment[d]
Rossi, 2001, Swiss Medical Weekly	7 centers in Switzerland, Swiss HIV Cohort Study	January 1990 to December 1999	Overall: 5.8/100 PY, 1990–1996: 8.8/100 PY, 1997–1999: 1.4/100 PY	Patient inclusion criteria: CD4 < 50 cells/mm^3; Disease definition: considers only the first episode after cohort enrollment
Brodt, 1997, AIDS	Frankfurt, Germany, Frankfurt AIDS Cohort	January 1992 to March 1997	1992: 4.5/100 PY; 1993: 6.1/100 PY; 1994: 6.6/100 PY; 1995: 5.4/100 PY; 1996: 2.8/100 PY;	Patient inclusion criteria: CD4 < 200 cells/mm^3, MSM only; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment
Kaplan, 2000, Clinical Infectious Diseases	10 US cities, Adults/Adolescents Spectrum of HIV Disease (ASD) Study	1992[c] to September 1999	1996–1998: 3.4/100 PY[e]	Patient inclusion criteria: no CD4 criteria; Disease definition: not clearly stated, likely considers all episodes after cohort enrollment

Table 4 (*Continued*)

First author, year, journal	Setting and cohort (when applicable)	Time period evaluated	Incidence rate estimate	Notes
Schwarcz, 2013, AIDS	San Francisco, US, SFDHP	January 1993 to December 2008	1993–1995: 8.52/100 PY; 1996–2000: 1.34/100 PY; 2001–2008: 0.32/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only the first episode after cohort enrollment
Kirk, 2000, American Journal of Respiratory and Critical Care Medicine	17 European countries, EuroSIDA Cohort	May 1994 to February 1999	1.38/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only the first episode after cohort enrollment
Mocroft, 2000, Lancet	51 centers in Europe, Eurosida cohort	May 1994 to spring 1999[c]	Non-ART regimens: 2.3/100 PY; ART regimens: 0.5/100 PY	Patient inclusion criteria: CD4 < 500 cells/mm^3; Disease definition: considers only the first episode after cohort enrollment
Baril, 2000, AIDS	Paris, France, Pitié-Salpêtrière Hospital	January 1995 to December 1997	January 1996 to June 1996: 13.4/100 PY; July 1996 to December 1997: 2.6/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers the first episode after cohort enrollment
Ledergerber, 1999, Journal of the American Medical Association	7 centers in Switzerland, Swiss HIV Cohort Study	September 1995 to March 1999	Before ART use: 1.79/100 PY; after ART use: 0.76/100 PY	Patient inclusion criteria: no CD4 criteria, patients who started ART between September 1995 and December 1997. Disease definition: considers only the first episode after cohort enrollment[d]
Wohl, 2003, Aids Patient Care and STDs	10 US cities, ASD cohort	1996[c] to 2000[c]	US born: 1.8/100 PY; Mexican born: 1.1/100 PY; Central American born: 0.4/100 PY	Patient inclusion criteria: no CD4 criteria; included US born Latinos, Mexican born Latinos and Central American Latinos. Disease definition: not clear stated, apparently included all OI presented in the study period
Low/middle-income settings				
Badri, 2005, The Southern African Journal of HIV Medicine	Cape Town, South Africa, Cape Town AIDS Cohort (CTAC)	1992[c] to December 2000	0.40/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: disseminated atypical mycobacteria; likely considers all episodes after cohort enrollment
Bonard, 2004, AIDS	Ivory Coast, Cotrame ANRS 1203	1992[c] to October 2002	1.85/100 PY	Patient inclusion criteria: no CD4 criteria; Disease definition: considers only the first episode after cohort enrollment[d]
Gadelha, 2002, The Brazilian Journal of Infectious Diseases	Rio de Janeiro, Brazil, IPEC cohort	September 1997 to December 1999	0	Patient inclusion criteria: CD4 < 100 cells/mm^3; Excluded patients under MAC treatment or prophylaxis. Disease definition: considers only the first episode presented in the study period

ART: highly active antiretroviral therapy; MAC: *Mycbacterium avium* complex; MSM: men who have sex with men; PCP: *Pneumocystis carinii* pneumonia.

[a] Time inferred from information contained in the text.

[b] Zidovudine, didanosine or both.

[c] Month not specified.

[d] Classify as *Mycobacterium* non tuberculosis.

[e] Results for other years shown in figure format only, thus not reported here.

Table 4, including results from England, France, Spain, Switzerland, and Germany.

In LMIS, two studies from Africa and one from Brazil report incidence rates of MAC. The South African study, with no CD4+ cell count restriction of the study population reported an incidence rate of 0.4/100 PY for the period of 1992–2000.[22] Another study, from Ivory Coast including all HIV-infected found an incidence rate of 1.85/100 PY for the period of 1992–2002.[24] The study from Brazil, conducted from 1997 to 1999 among patients with CD4+ cell counts less than 100 cells/mm^3 reported no cases of disseminated MAC.[25]

Discussion

Through a systematic review of the literature, we have shown that the incidence of opportunistic illnesses decreased over the 30 years of the HIV epidemic, markedly after ART availability. The significant reduction in the incidence rates was demonstrated for opportunistic illnesses overall and also for specific opportunistic infections, namely, PCP, NXT and MAC. In addition, the decreasing trends were shown for both HIS and LMIS where ART was made available. This result is extremely positive as it shows that opportunistic illnesses can be controlled while also pointing to the persistent challenge of a timely diagnosis of HIV infection. Indeed, in order to control opportunistic illnesses HIV infection status must be identified and earlier linkage to care needs to be facilitated. That is, a higher uptake of HIV testing with direct linkage to care of those found to be HIV-infected is urgently needed.

We found that the magnitude of the incidence rates and of the reduction of these rates as a function of ART varied between studies. Indeed, it is well known that there are geographical differences in the incidence of opportunistic illnesses.[26] Other reasons for the differences in the baseline rates might include different study populations, including different sociodemographic subgroups evaluated in a specific study, for example, the MACS cohort that focuses on men who have sex men,[27] as well as different inclusion criteria. Some studies included all HIV-infected individuals while others restricted the study population to individuals with specific CD4+ cell counts, for example, including only those with CD4+ cell count less than 100 cells/mm^3.[15] Moreover, different study definitions with respect to the diseases chosen to be included in any given study might have further contributed to the disparate results.

Out of the 37 studies included in the present review, almost 70% were from HIS. Of the 12 studies from LMIS, four studies were from Brazil.[13–15,25] These studies reported incidence rates for opportunistic illnesses for the entire study period included in the respective study and not annual rates that could allow us to evaluate the temporal trends in incidence. Also, only one study from Brazil reported separately on the incidence rate of MAC. However, this study reported no cases of the disease, a finding that could have been due to the small sample size and/or short follow-up. For other important diseases that define the AIDS epidemic, namely, PCP, and NXT, no studies from Brazil were found. Furthermore, all are single center cohort studies, two from São Paulo (Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo) and two from Rio de Janeiro (Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz). We believe that the description of the trends in incidence rates of opportunistic illnesses is of paramount value to health care providers to guide clinical decision-making and policy makers to define priorities for care and prevention of opportunistic infections.

Strengths and limitations to the present study are worth mentioning. Through a systematic review conducted in four databases we found the epidemiological studies that reported on the incidence rate of opportunistic illnesses. We restricted the review to those studies reporting on rates (and not overall numbers or frequencies) since this epidemiological parameter is adjusted for population size and time under risk thus allowing for comparisons between studies. Though not a limitation of our study design and approach, the scarcity of studies from LMIS implies that we cannot adequately describe the patterns of incidence in these settings. In addition, the few studies found should also not be understood as representative of entire countries as they report from one center only. Finally, the different study methodologies such as inclusion criteria and diseases included, for example, limited the comparisons.

In conclusion, the incidence rate of opportunistic illnesses has decreased over time mainly due to the availability of highly effective, safe and well tolerated ART. However, a public health challenge remains for future years. Public health policies focusing on earlier HIV diagnosis and linkage to care, adherence and retention programs, and surveillance of HIV multidrug resistance in populations should be developed and implemented with the goal of improving the quality of life and reducing morbidity and mortality among HIV-infected individuals. To better understand the nuances of the epidemiology of opportunistic illnesses in LMIS, multicenter cohort studies should be encouraged. Finally, it is clear that studies from Brazil are urgently needed to assess the current burden of opportunistic illnesses in order to support the planning of HIV/AIDS health care services organization.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2012; 2012.
2. Buchacz K, Baker RK, Palella Jr FJ, Chmiel JS, Lichtenstein KA, Novak RM, et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS. 2010;24:1549–59.
3. Pacheco AG, Tuboi SH, May SB, Moreira LFS, Ramadas L, Nunes EoP, et al. Temporal changes in causes of death among

HIV-infected patients in the HAART Era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2009;51:624–30, http://dx.doi.org/10.1097/QAI.0b013e3181a4ecf5.

4. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8:e59768.

5. Perbost I, Malafronte B, Pradier C, Santo LD, Dunais B, Counillon E, et al. In the era of highly active antiretroviral therapy, why are HIV-infected patients still admitted to hospital for an inaugural opportunistic infection? HIV Med. 2005;6:232–9.

6. Cardoso SW, Grinsztejn B, Velasque L, Veloso VG, Luz PM, Friedman RK, et al. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses. 2010;26:865–74.

7. Hacker MA, Kaida A, Hogg RS, Bastos FI. The first ten years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996–2006. Cad Saude Publica. 2007;23 Suppl 3:S345–59.

8. Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy adherence in Brazil. AIDS. 2004;18 Suppl 3:S15–20.

9. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023–35.

10. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet. 2000;356:291–6.

11. San-Andres FJ, Rubio R, Castilla J, Pulido F, Palao G, de Pedro I, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989–1997. Clin Infect Dis. 2003;36:1177–85.

12. Rojanawiwat A, Tsuchiya N, Pathipvanich P, Pumpradit W, Schmidt W-P, Honda S, et al. Impact of the National Access to Antiretroviral Program on the incidence of opportunistic infections in Thailand. International Health. 2011;3: 101–7.

13. Fonseca LA, Reingold AL, Casseb JR, Brigido LF, Duarte AJ. AIDS incidence and survival in a hospital-based cohort of asymptomatic HIV seropositive patients in Sao Paulo, Brazil. Int J Epidemiol. 1999;28:1156–60.

14. Casseb J, Fonseca LA, Veiga AP, de Almeida A, Bueno A, Ferez AC, et al. AIDS incidence and mortality in a hospital-based cohort of HIV-1-seropositive patients receiving highly active antiretroviral therapy in Sao Paulo, Brazil. AIDS Patient Care STDS. 2003;17:447–52.

15. Gadelha AJ, Accacio N, Costa RL, Galhardo MC, Cotrim MR, de Souza RV, et al. Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo. 2002;44:179–86.

16. Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Devereux H, et al. Changes in AIDS-defining illnesses in a London Clinic, 1987–1998. J Acquir Immune Defic Syndr. 1999;21:401–7.

17. Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS. 2013;27:597–605.

18. Hung CC, Chen MY, Hsieh SM, Sheng WH, Chang SC. Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. J Acquir Immune Defic Syndr. 2000;24:378–85.

19. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56:257–60.

20. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. J Am Med Assoc. 1999;282:2220–6.

21. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol. 2011;18:527–34.

22. Badri M, Maartens G, Bekker LG, Wood R. The spectrum and prognosis of AIDS-defining illnesses in Cape Town. S Afric J HIV Med. 2005;6:11–6.

23. Rossi M, Flepp M, Telenti A, Schiffer V, Egloff N, Bucher H, et al. Disseminated *M. avium* complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy. Swiss Med Wkly. 2001;131:471–7.

24. Bonard D, Messou E, Seyler C, Vincent V, Gabillard D, Anglaret X. High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Cote d'Ivoire. AIDS. 2004;18:1961–4.

25. Gadelha A, Accacio N, Grinsztejn B, Veloso V, da Silveira LB, Fandinho F, et al. Low incidence of colonization and no cases of disseminated *Mycobacterium avium* complex infection (DMAC) in Brazilian AIDS patients in the HAART Era. Braz J Infect Dis. 2002;6:252–7.

26. Yazdanpanah Y, Chene G, Losina E, Goldie SJ, Merchadou LD, Alfandari S, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001;30: 864–71.

27. Cain LE, Cole SR, Greenland S, Brown TT, Chmiel JS, Kingsley L, et al. Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. Am J Epidemiol. 2009;169:1124–32.

28. Bacellar H, Munoz A, Hoover DR, Phair JP, Besley DR, Kingsley LA, et al. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4$^+$ cell counts <100/mm^3. Multicenter AIDS Cohort Study. J Infect Dis. 1994;170: 1284–7.

29. Baril L, Jouan M, Agher R, Cambau E, Caumes E, Bricaire F, et al. Impact of highly active antiretroviral therapy on onset of *Mycobacterium avium* complex infection and cytomegalovirus disease in patients with AIDS. AIDS. 2000;14:2593–6.

30. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS. 1997;11: 1731–8.

31. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of *Mycobacterium avium*-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis. 1992;146:285–9.

32. Charurat M, Blattner W, Hershow R, Buck A, Zorrilla CD, Watts DH, et al. Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt). 2004;13:719–30.

33. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndeye GF, Sow PS, et al. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect Dis. 2010;10:179.

34. Forrest DM, Seminari E, Hogg RS, Yip B, Raboud J, Lawson L, et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis. 1998;27:1379–85.

35. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in

Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42:464–9.

36. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30 Suppl 1:S5–14.

37. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, et al. Infections with *Mycobacterium tuberculosis* and *Mycobacterium avium* among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med. 2000;162 3 Pt 1:865–72.

38. Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir Ther. 2007;12:543–51.

39. Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P, Johnson MA, et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch Intern Med. 1998;158:491–7.

40. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996;124:633–42.

41. Moorman AC, Von Bargen JC, Palella FJ, Holmberg SD. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:182–8.

42. Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, et al. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection. 2011;39:3–12.

43. Podlasin RB, Wiercinska-Drapalo A, Olczak A, Beniowski M, Smiatacz T, Malolepsza E, et al. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000–2002. Infection. 2006;34:196–200.

44. Riveiro-Barciela M, Falco V, Burgos J, Curran A, Van den Eynde E, Navarro J, et al. Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital. HIV Med. 2013;14:21–30.

45. Wohl AR, Lu S, Turner J, Kovacs A, Witt M, Squires K, et al. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS. 2003;17:267–75.